OBJECTIVES: The aim of this study was assess serum ischemia modified albumin (IMA) in type 2 diabetes patients and determine its correlation with other risk factors for chronic complications such as inflammation and hyperglycemia. DESIGN AND METHODS: Fasting glucose, glycated albumin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, uric acid, albumin, lactic acid, high-sensitivity C-reactive protein (hs-CRP) and IMA were measured in 80 patients with type 2 diabetes and 26 controls. RESULTS: Fasting glucose, glycated albumin, triglycerides, creatinine, IMA and hs-CRP were significantly higher in patients with type 2 diabetes. Correlations were weak but significant between IMA and fasting glucose, IMA and hs-CRP, hs-CRP and HDL cholesterol and hs-CRP and fasting glucose were observed. CONCLUSIONS: We have shown higher levels of IMA and hs-CRP in type 2 diabetes. Hyperglycemia and inflammation reduces the capacity of albumin to bind cobalt, resulting in higher IMA levels. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: The aim of this study was assess serum ischemia modified albumin (IMA) in type 2 diabetespatients and determine its correlation with other risk factors for chronic complications such as inflammation and hyperglycemia. DESIGN AND METHODS: Fasting glucose, glycated albumin, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, creatinine, uric acid, albumin, lactic acid, high-sensitivity C-reactive protein (hs-CRP) and IMA were measured in 80 patients with type 2 diabetes and 26 controls. RESULTS: Fasting glucose, glycated albumin, triglycerides, creatinine, IMA and hs-CRP were significantly higher in patients with type 2 diabetes. Correlations were weak but significant between IMA and fasting glucose, IMA and hs-CRP, hs-CRP and HDL cholesterol and hs-CRP and fasting glucose were observed. CONCLUSIONS: We have shown higher levels of IMA and hs-CRP in type 2 diabetes. Hyperglycemia and inflammation reduces the capacity of albumin to bind cobalt, resulting in higher IMA levels. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors: Renata da Silva Pereira; Etiane Tatsch; Guilherme Vargas Bochi; Helena Kober; Thiago Duarte; Greice Franciele Feyh dos Santos Montagner; José Edson Paz da Silva; Marta Maria Medeiros Frescura Duarte; Ivana Beatrice Mânica da Cruz; Rafael Noal Moresco Journal: Inflammation Date: 2013-08 Impact factor: 4.092
Authors: S V Reddy; M M Suchitra; V Pradeep; S Alok; V Suresh; A R Bitla; P V L N Srinivasa Rao Journal: J Endocrinol Invest Date: 2015-04-11 Impact factor: 4.256
Authors: E Cakir; M Ozbek; E Ozkaya; N Colak; E Cakal; M Sayki; A Gungunes; Y Aliyazicioglu; A Mentese; T Delibasi Journal: J Endocrinol Invest Date: 2010-11-16 Impact factor: 4.256
Authors: Sílvia Juliane Piva; Etiane Tatsch; José Antonio Mainardi De Carvalho; Guilherme Vargas Bochi; Helena Kober; Thiago Duarte; Marta Maria Medeiros Frescura Duarte; Ivana Beatrice Mânica da Cruz; Maria Beatriz Moretto; Rafael Noal Moresco Journal: Inflammation Date: 2013-02 Impact factor: 4.092